Akari Therapeutics ADR (AKTX) Stock Price, Quote & News

Company Profile

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon,...

Industry: Biotechnology

Sector: Healthcare

Phone: 929 274 7510

Fax: 929 274 7553

Website: www.akaritx.com

Address:

401 East Jackson Street, Suite 3300, Tampa, United States

akaritx Jul. 22 at 1:16 PM

$AKTX CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity https://bit.ly/4pxlXqH

0 · Reply

VincenzoPaol Jul. 21 at 9:48 PM

$AKTX it is way to cheap not much downside from this prices!

0 · Reply

stockscan Jul. 21 at 3:46 PM

$AKTX

0 · Reply

MadStockAlerts1 Jul. 21 at 1:18 PM

Premarket top gainers (1/2) $UTZ +88.5% ($14.04) UTZ $FWRD +19.7% ($15.81) FWRD $LASE +15.6% ($1.26) LASE $RPT +13.9% ($12.11) RPT $AKTX +10.7% ($11.80) AKTX

0 · Reply

akaritx Jul. 21 at 1:12 PM

$AKTX Enters Strategic Research Collaboration with Whitehawk Therapeutics https://bit.ly/4fN2XRy

0 · Reply

Nutflush Jul. 21 at 11:17 AM

$AKTX she's moving

1 · Reply

notreload_ai Jul. 20 at 5:15 PM

Maxim Group upgrades $AKTX to Buy with a $30 price target, citing strong AKTX-101 ADC data, fresh $8.3M capital, and ADC sector tailwinds. https://notreload.xyz/xy/aktx-strengthens-balance-sheet-and-prepares-phase-1-as-maxim-raises-rating-to-buy/

0 · Reply